Details
Stereochemistry | RACEMIC |
Molecular Formula | C13H16N2 |
Molecular Weight | 200.2795 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CN=C(N1)C2CCCC3=C2C=CC=C3
InChI
InChIKey=BYJAVTDNIXVSPW-UHFFFAOYSA-N
InChI=1S/C13H16N2/c1-2-6-11-10(4-1)5-3-7-12(11)13-14-8-9-15-13/h1-2,4,6,12H,3,5,7-9H2,(H,14,15)
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095203 Sources: www.ncbi.nlm.nih.gov/pubmed/18259967 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | TYZINE Approved UseTyzine Nasal Solution is indicated for decongestion of nasal and nasopharyngeal mucosa. Launch Date1979 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.218 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21972870/ |
2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered: |
TETRAHYDROZOLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.46 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21972870/ |
2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered: |
TETRAHYDROZOLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21972870/ |
2 drop 4 times / day multiple, ocular dose: 2 drop route of administration: Ocular experiment type: MULTIPLE co-administered: |
TETRAHYDROZOLINE serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
7500 ug single, oral Overdose |
healthy, 16 years n = 1 Health Status: healthy Age Group: 16 years Sex: M Population Size: 1 Sources: |
Other AEs: Sinoatrial node dysfunction... |
0.3 mg/kg single, oral Overdose Dose: 0.3 mg/kg Route: oral Route: single Dose: 0.3 mg/kg Sources: |
healthy, 20 months-2 years n = 2 Health Status: healthy Age Group: 20 months-2 years Sex: M+F Population Size: 2 Sources: |
Other AEs: Bradycardia, Hypertension... Other AEs: Bradycardia (2 patients) Sources: Hypertension (1 patient) Gasping (2 patients) |
250 ug 3 times / day multiple, oral Overdose Dose: 250 ug, 3 times / day Route: oral Route: multiple Dose: 250 ug, 3 times / day Sources: |
unhealthy, 25 days n = 1 Health Status: unhealthy Age Group: 25 days Sex: M Population Size: 1 Sources: |
Other AEs: Hypotonia... |
250 ug 3 times / day multiple, oral Overdose Dose: 250 ug, 3 times / day Route: oral Route: multiple Dose: 250 ug, 3 times / day Sources: |
unhealthy, 25 days n = 1 Health Status: unhealthy Condition: mild fever Age Group: 25 days Sex: M Population Size: 1 Sources: |
Other AEs: Apnea... |
15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Other AEs: Hypothermia, Bradycardia... Other AEs: Hypothermia (1 patient) Sources: Bradycardia (1 patient) Hypotension (1 patient) Miosis (1 patient) Lethargy (1 patient) Mucous membrane disorder (NOS) (1 patient) Bowel sounds decreased (1 patient) Chest pain (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Sinoatrial node dysfunction | 1 patient | 7500 ug single, oral Overdose |
healthy, 16 years n = 1 Health Status: healthy Age Group: 16 years Sex: M Population Size: 1 Sources: |
Hypertension | 1 patient | 0.3 mg/kg single, oral Overdose Dose: 0.3 mg/kg Route: oral Route: single Dose: 0.3 mg/kg Sources: |
healthy, 20 months-2 years n = 2 Health Status: healthy Age Group: 20 months-2 years Sex: M+F Population Size: 2 Sources: |
Bradycardia | 2 patients | 0.3 mg/kg single, oral Overdose Dose: 0.3 mg/kg Route: oral Route: single Dose: 0.3 mg/kg Sources: |
healthy, 20 months-2 years n = 2 Health Status: healthy Age Group: 20 months-2 years Sex: M+F Population Size: 2 Sources: |
Gasping | 2 patients | 0.3 mg/kg single, oral Overdose Dose: 0.3 mg/kg Route: oral Route: single Dose: 0.3 mg/kg Sources: |
healthy, 20 months-2 years n = 2 Health Status: healthy Age Group: 20 months-2 years Sex: M+F Population Size: 2 Sources: |
Hypotonia | 1 patient | 250 ug 3 times / day multiple, oral Overdose Dose: 250 ug, 3 times / day Route: oral Route: multiple Dose: 250 ug, 3 times / day Sources: |
unhealthy, 25 days n = 1 Health Status: unhealthy Age Group: 25 days Sex: M Population Size: 1 Sources: |
Apnea | 1 patient | 250 ug 3 times / day multiple, oral Overdose Dose: 250 ug, 3 times / day Route: oral Route: multiple Dose: 250 ug, 3 times / day Sources: |
unhealthy, 25 days n = 1 Health Status: unhealthy Condition: mild fever Age Group: 25 days Sex: M Population Size: 1 Sources: |
Bowel sounds decreased | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Bradycardia | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Chest pain | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Hypotension | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Hypothermia | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Lethargy | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Miosis | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
Mucous membrane disorder (NOS) | 1 patient | 15000 ug single, oral Overdose Dose: 15000 ug Route: oral Route: single Dose: 15000 ug Sources: |
healthy, 41 years n = 1 Health Status: healthy Age Group: 41 years Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Gingival tissue inflammatory response following treatment with chemical retraction agents in Beagle dogs. | 2001 |
|
Viability of fibroblasts in cell culture after treatment with different chemical retraction agents. | 2002 Jan |
|
Electron microscopic analysis of the effects of chemical retraction agents on cultured rat keratinocytes. | 2002 Jan |
|
Gingival inflammatory response induced by chemical retraction agents in beagle dogs. | 2002 Jan-Feb |
|
Simultaneous determination of ofloxacin, tetrahydrozoline hydrochloride, and prednisolone acetate by high-performance liquid chromatography. | 2002 Sep |
|
Pediatric Visine (tetrahydrozoline) ingestion: case report and review of imidazoline toxicity. | 2003 Aug |
|
Transdermal penetration of vasoconstrictors--present understanding and assessment of the human epidermal flux and retention of free bases and ion-pairs. | 2003 Feb |
|
[The tolerability of nasal drugs with special regard to preservatives and physico-chemical parameters]. | 2003 Nov |
|
[Acute exposure to imidazoline derivatives in children]. | 2003 Nov-Dec |
|
Sinoatrial node arrest following tetrahydrozoline ingestion. | 2004 Oct |
|
Effects of two eye drop products on computer users with subjective ocular discomfort. | 2005 Jan |
|
[Systemic involvement in premature infants after intranasal administration of tetryzoline drops]. | 2005 Oct |
|
Simple HPLC determination of benzalkonium chloride in ophthalmic formulations containing antazoline and tetrahydrozoline. | 2005 Sep-Oct |
|
[Drug administration in newborns. Is clinical experience enough?]. | 2006 Apr |
|
Ophthalmic delivery systems based on drug-polymer-polymer ionic ternary interaction: in vitro and in vivo characterization. | 2006 Jan |
|
Antagonism by imidazoline-type drugs of muscarinic and other receptors in the guinea-pig ileum. | 2006 Jul |
|
Drug facilitated sexual assault using an over-the-counter ocular solution containing tetrahydrozoline (Visine). | 2007 Jul |
|
Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. | 2008 Feb |
|
Development of a multicommutated flow system with chemiluminometric detection for quantification of gentamicin in pharmaceuticals. | 2010 |
|
Determination of tetrahydrozoline in urine and blood using gas chromatography-mass spectrometry (GC-MS). | 2010 |
|
2-(1,2,3,4-Tetra-hydro-1-naphth-yl)imidazolium chloride monohydrate. | 2010 Aug 18 |
|
Naloxone use in a newborn with apnea due to tetrahydrozoline intoxication. | 2010 Jun |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
Tetrahydrozoline (Visine®) concentrations in serum and urine during therapeutic ocular dosing: a necessary first step in determining an overdose. | 2011 Nov |
Sample Use Guides
Adults and Children 6 Years and Over, Tyzine 0.1% Nasal Solution: It is recommended that 2 to 4 drops be instilled in each nostril as needed, never more often than every three hours. Adults and Children 6 Years and Over, Tyzine 0.1% Nasal Spray: It is recommended to squeeze quickly and firmly three or four times the spray in each nostril as needed, never more often than every three hours. Children 2 to 6 Years of Age, Tyzine 0.05 % Pediatric Nasal Drops: It is recommended that 2 to 3 drops be instilled in each nostril as needed, and never more often than every three hours.
Route of Administration:
Nasal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6289955
Rat and rabbit aortae were treated with tetrahydrozoline at concentrations from 10(-7) to 10(-5) M to determine the drug relative efficacy. Emax value was 0.51 for the rabbit aortae and 0 for the rat aortae.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QS01GA02
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
||
|
WHO-ATC |
R01AB03
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
||
|
NCI_THESAURUS |
C29709
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
||
|
WHO-VATC |
QR01AA06
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
||
|
WHO-VATC |
QS01GA52
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
||
|
WHO-VATC |
QR01AB03
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
||
|
WHO-ATC |
S01GA02
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
||
|
WHO-ATC |
S01GA52
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
||
|
WHO-ATC |
R01AA06
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
519
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | |||
|
DB06764
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | |||
|
3591
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | |||
|
m10634
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | Merck Index | ||
|
201-522-3
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | |||
|
28674
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | |||
|
TETRAHYDROZOLINE
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | |||
|
7471
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | |||
|
84-22-0
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | |||
|
100000082723
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | |||
|
CHEMBL1266
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | |||
|
DTXSID1047861
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | |||
|
5419
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | |||
|
S9U025Y077
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | |||
|
37935
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | RxNorm | ||
|
S9U025Y077
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | |||
|
SUB10955MIG
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY | |||
|
C61967
Created by
admin on Fri Dec 15 15:06:00 GMT 2023 , Edited by admin on Fri Dec 15 15:06:00 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)